Welcome to our dedicated page for Aileron Therapeutics news (Ticker: ALRN), a resource for investors and traders seeking the latest updates and insights on Aileron Therapeutics stock.
About Aileron Therapeutics Inc.
Aileron Therapeutics Inc. (NASDAQ: ALRN) is a clinical-stage biopharmaceutical company dedicated to advancing a novel pipeline of first-in-class medicines that address significant unmet medical needs in orphan pulmonary, fibrotic, and oncology indications. With a strong foundation in peptide therapeutics, Aileron is at the forefront of developing innovative therapies designed to improve patient outcomes in challenging and underserved medical conditions.
Core Product Pipeline
LTI-03: Aileron's lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism of action targeting alveolar epithelial cell survival and inhibition of profibrotic signaling. Currently in clinical development, LTI-03 has shown promise in treating idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. The therapy's unique approach aims to not only slow disease progression but potentially restore healthy lung function.
LTI-01: Another key asset in Aileron's pipeline, LTI-01, is a proenzyme developed for loculated pleural effusions. Having completed Phase 1b and Phase 2a clinical trials, LTI-01 has received Orphan Drug Designation in both the U.S. and EU, as well as Fast Track Designation in the U.S., underscoring its potential to address critical unmet needs in this condition.
ALRN-6924: Previously a lead oncology candidate, ALRN-6924 is a clinical-stage therapy that reactivates the tumor-suppressing protein p53 by targeting MDMX and MDM2. This innovative approach has positioned ALRN-6924 as the first and only clinical-stage drug targeting MDMX, with potential applications in rare cancers like retinoblastoma.
Market Position and Competitive Edge
Aileron Therapeutics operates in the highly specialized fields of peptide-based therapeutics and orphan disease indications. By focusing on first-in-class therapies, the company differentiates itself from competitors through its innovative mechanisms of action and targeted approach to high-need patient populations. Its strategic focus on orphan diseases, supported by Orphan Drug and Fast Track designations, positions it to capitalize on regulatory incentives and market exclusivity.
Industry Significance
As a pioneer in peptide therapeutics, Aileron Therapeutics is contributing to the advancement of treatments for complex diseases with limited existing options. Its commitment to addressing unmet medical needs in IPF, fibrosis, and oncology aligns with broader industry trends emphasizing innovation in rare and life-threatening diseases. With a robust clinical pipeline and a focus on leveraging cutting-edge science, Aileron is poised to make a meaningful impact on patient care and the biopharmaceutical landscape.
Aileron Therapeutics (Nasdaq: ALRN) announced the termination of its Phase 1b trial for ALRN-6924 in patients with p53-mutated breast cancer due to severe adverse events, including Grade 4 neutropenia and alopecia. The trial assessed the drug's efficacy alongside TAC chemotherapy. Aileron is now exploring strategic alternatives to enhance shareholder value, including potential acquisition or merger opportunities, with Ladenburg Thalmann as a strategic advisor. The company's workforce will be reduced from nine to three employees. Aileron's ALRN-6924 had shown promise in prior trials, but these latest findings have necessitated a shift in focus.
Aileron Therapeutics (Nasdaq: ALRN) announced on November 30, 2022, that it has regained compliance with Nasdaq's minimum bid price requirement. The Nasdaq Stock Market confirmed that Aileron’s closing bid price exceeded $1.00 per share for 10 consecutive business days, ending November 25, 2022. This compliance allows the company to maintain its listing. Aileron focuses on developing ALRN-6924, a chemoprotective agent targeting p53-mutated cancers, aiming to enhance chemotherapy efficacy while reducing side effects.
Aileron Therapeutics (Nasdaq: ALRN) announced a 1-for-20 reverse stock split of its common stock effective at 5:00 p.m. ET on November 10, 2022. The split aims to comply with Nasdaq’s minimum bid price requirement, reducing the number of outstanding shares from approximately 90.8 million to 4.5 million. Trading on a split-adjusted basis will begin on November 11, 2022. No fractional shares will be issued; instead, stockholders will receive cash payments for any fractional shares. This transition affects all stockholders uniformly without altering their percentage interests.
Aileron Therapeutics (ALRN) has activated multiple sites for its Phase 1b breast cancer trial, with additional site activations expected in Q4 2022 and Q1 2023. Recent presentations highlighted the potential of ALRN-6924 to prevent chemotherapy-induced toxicities, including neutropenia and alopecia. Cash reserves stood at $25.5 million, expected to fund operations through Q1 2024. R&D expenses were stable at $4.2 million, while G&A expenses decreased to $2.2 million. The net loss for Q3 2022 was $6.4 million, consistent with the previous year.
Aileron Therapeutics (Nasdaq: ALRN) presented results from its Phase 1 study of ALRN-6924 at the EORTC-NCI-AACR conference. The study demonstrated ALRN-6924's potential to prevent chemotherapy-induced side effects, including neutropenia, thrombocytopenia, and alopecia, by inducing p53-mediated cell cycle arrest in bone marrow stem cells and hair follicles. Aileron selected a 1.2 mg/kg dose for its ongoing Phase 1b trial in p53-mutated breast cancer patients. Safety profiles were consistent across administration methods, suggesting a simplified bolus option for future use.
Aileron Therapeutics (Nasdaq: ALRN) announced new ex vivo data demonstrating that ALRN-6924 protects hair follicles from damage caused by chemotherapy agents cyclophosphamide and taxanes. During a presentation at the European Society for Dermatological Research, findings highlighted ALRN-6924's ability to temporarily arrest the cell cycle in scalp hair follicles and stem cells, potentially preventing alopecia. This agent is currently evaluated in an ongoing Phase 1b trial focused on breast cancer patients, aiming to reduce chemotherapy-induced side effects. Anticipated trial results are expected in late 2022 and throughout 2023.
Aileron Therapeutics (Nasdaq: ALRN) announced that Dr. Manuel Aivado, President and CEO, will present at the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022, at 3:30 p.m. ET in New York. A webcast of the presentation will be available on their website and archived for 30 days. Aileron, a clinical-stage oncology company, focuses on making chemotherapy safer with their drug ALRN-6924, designed to protect healthy cells during treatment while targeting cancer cells. This innovation aims to improve the quality of life for patients with p53-mutated cancers.
Aileron Therapeutics (Nasdaq: ALRN) has announced a pre-recorded corporate presentation scheduled for September 12, 2022, at 7:00 a.m. ET, during the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will focus on the company's chemoprotection oncology efforts to enhance chemotherapy safety and effectiveness. It will be accessible on-demand through the company's website and archived for 30 days. Aileron's lead product, ALRN-6924, targets p53-mutated cancers, aiming to improve patients' quality of life and treatment tolerability.
Aileron Therapeutics (Nasdaq: ALRN) has reported advancements on ALRN-6924, focusing on its clinical trial for breast cancer patients with p53 mutations. The company has extended its cash runway to support operations through Q1 2024. Recent data suggests ALRN-6924 could protect against chemotherapy-induced alopecia and prevent damage to hair follicle stem cells. The company also appointed Susan L. Drexler as interim CFO and strengthened its intellectual property portfolio with a new patent in China. For Q2 2022, Aileron reported an $8 million net loss, with cash standing at $32.4 million.
Aileron Therapeutics (Nasdaq: ALRN) announced enhancements to its Phase 1b trial of ALRN-6924 for p53-mutated breast cancer, aiming to improve chemoprotection against chemotherapy-induced severe neutropenia and alopecia. Key updates include increasing the dose to 1.2 mg/kg and modifying the primary endpoint to focus on severe neutropenia in cycle 1. The trial’s cash runway is extended through Q1 2024, enabling topline results to potentially support a pivotal trial. Readouts are expected in 4Q 2022, 2Q 2023, and 3Q 2023.
FAQ
What is the current stock price of Aileron Therapeutics (ALRN)?
What is the market cap of Aileron Therapeutics (ALRN)?
What does Aileron Therapeutics Inc. specialize in?
What are Aileron's key product candidates?
How does LTI-03 work?
What regulatory designations has Aileron received?
What differentiates Aileron from its competitors?
What is ALRN-6924, and what does it target?
What is idiopathic pulmonary fibrosis (IPF)?
What are the risks associated with Aileron's clinical programs?
